What are you actually buying?
Four things, and their relative value determines whether a price is sensible.
An NHS contract, where one exists, which is the asset that cannot readily be replicated and which accounts for much of why established pharmacies command the prices they do.
A patient base, being the prescriptions which arrive without being won, subject to the qualification that patient loyalty attaches partly to the departing owner and staff rather than wholly to the premises.
Trading history, which supports lending, informs valuation and, as this library notes in respect of payments underwriting, materially assists in obtaining the commercial arrangements a new business struggles to secure.
An operating business, comprising staff, systems, procedures and a compliance history, which is an asset where it is good and a liability where it is not.
The fourth is where purchases go wrong. A buyer acquiring a business with weak records, unresolved inspection findings or procedures which do not reflect practice has bought a remediation project priced as a going concern, and the work falls due immediately whilst the price assumed it would not.
What does starting one give you?
Nothing, except the ability to build it properly, which is worth more than it sounds and less than founders assume.
The genuine advantages are structural. Systems, procedures and records can be built to the standard this library describes rather than retrofitted, which matters given that the inspection data identifies governance as the dominant failure area. The model can be chosen deliberately, whether private, distance-selling or a hybrid. There is no inherited staffing, lease, reputation or regulatory history. And the cost base can be sized to the actual business rather than to the one somebody else ran.
The disadvantages are equally structural. There is no revenue for a period which is usually longer than planned. There is no trading history, which affects lending, acquiring, insurance and supplier terms simultaneously. Demand must be built, and in private services that is a marketing and retention problem rather than a dispensing one. And the NHS contract question, addressed next, constrains what kind of business can realistically be started at all.
Can you still obtain a new NHS contract?
Rarely, and this single fact shapes the entire market-entry landscape.
Entry to the NHS pharmaceutical services list operates through the pharmaceutical needs assessment framework, under which an application generally must demonstrate that it meets a need identified in the relevant assessment, or offers unforeseen benefits. Applications succeed, and they are not the ordinary route into ownership.
Two consequences follow. First, the price of an existing pharmacy embeds the scarcity of the contract attached to it, which is why buying frequently costs more than the trading figures alone would justify. Second, new entrants are pushed toward the models which do not depend upon a conventional contract, comprising distance-selling pharmacy and private services, which is precisely the territory this site covers in depth and which explains why so much of the sector's new entry is arriving there.
An aspiring owner attracted by the idea of opening a high street pharmacy should establish the position in their intended area early, because it determines whether the plan is a plan or an aspiration.
How are pharmacies valued?
Ordinarily as a multiple of adjusted earnings, with goodwill dominating because the tangible assets are modest. The multiple reflects a set of judgements about durability rather than a formula, and the factors which move it are worth understanding from both sides of a transaction.
| Raises the multiple | Lowers it |
|---|---|
| Stable NHS volume with a settled local prescribing base | Volume dependent on one surgery or one prescriber relationship |
| Established private service income with genuine retention | Private income which is recent, promotional or unrepeatable |
| Long lease on sensible terms, or freehold | Short lease, break clauses, or rent above market |
| Staff who will remain, with the business not dependent on the owner | An owner-operator whose departure removes the pharmacist and the relationships |
| Clean regulatory history and records which evidence practice | Unresolved findings, weak documentation, or an inspection due |
The line which sellers underestimate and buyers should press hardest is the fourth. A pharmacy whose owner is also its only regular pharmacist, and whose patients come because of that person, is selling something which partly leaves with the seller. That should be reflected in the price, in the handover period, or in both.
What should diligence uncover?
Buyers instruct accountants to examine the accounts and solicitors to examine the contracts, and frequently examine the regulatory position last or not at all, which inverts the risk. A pharmacy's compliance history bears directly upon its future income, because an unresolved inspection finding is remediation work with a deadline, a weak record system is a rebuild, a payments relationship secured on inaccurate disclosures is an account which may not survive a change of ownership, and a superintendent arrangement which was never properly documented is a problem the buyer inherits on completion. The items to request are unglamorous and specific. Inspection reports and every action arising from them, with evidence of closure. The current procedures, compared against what the team actually does. The near-miss and incident log, since its absence is itself a finding. Responsible pharmacist records. Controlled drugs registers and destruction records. Private service documentation including prescribing arrangements and patient records. And confirmation of what the regulator has been told about ownership and superintendent arrangements. A seller who can produce these quickly is telling a buyer something valuable about the business. A seller who cannot is telling them something more valuable still.
Share purchase or asset purchase?
The distinction carries tax, regulatory, employment and liability consequences, and a buyer should reach it as a decision rather than as a default proposed by whoever drafted first.
A share purchase acquires the company itself, with its history, its contracts and its liabilities intact, which preserves continuity but means historic exposure comes too. It generally keeps arrangements in place without renegotiation, and it places a premium upon warranties and indemnities because the buyer is inheriting whatever has not been disclosed.
An asset purchase acquires selected assets and generally leaves historic liabilities with the seller, at the cost of having to reconstitute the position, which touches the regulatory registration, the NHS arrangements, supplier accounts, the lease and employment obligations. It is cleaner on liability and more work on continuity.
Both routes require the regulatory position to be addressed properly, since ownership of a registered pharmacy and the superintendent arrangements are matters the GPhC records and expects to be accurate and timely, and a transaction which completes commercially before the regulatory steps are in hand has created a gap somebody will have to explain.
What costs do both routes underestimate?
Five, and they apply to buyers and founders alike.
Working capital for stock, which for a dispensing business is substantial and is frequently modelled as an afterthought.
The remediation period after a purchase, during which procedures, records and systems are brought to standard whilst the business trades.
Professional fees, comprising legal, accountancy and regulatory advice, which are worth paying properly precisely because this is the transaction where economising is most expensive.
The commercial arrangements a new business cannot yet obtain, comprising acquiring terms, supplier credit and insurance priced without trading history, which is a real cost rather than an inconvenience.
Owner time, which in the first year is consumed by matters that produce no revenue and which is the reason a plan requiring the owner to also dispense full time is usually a plan that fails.
Which route suits which owner?
The honest test is not financial but temperamental, and it comes down to which kind of work an owner does well.
Buying suits an owner who improves things, who is comfortable inheriting arrangements and correcting them, who needs income from the outset, and who can conduct or commission proper diligence. It particularly suits a pharmacist who intends to work in the business and wants an existing patient base to build upon.
Starting suits an owner with a specific model in view, particularly in private or distance-selling services, who can fund a period without revenue, who is prepared for the demand-building work to be the actual job, and who values building systems correctly over acquiring them quickly.
The route which suits almost nobody is buying a pharmacy in order to convert it into something entirely different, since the buyer pays for an NHS contract and a patient base whilst intending to build a business which uses neither, and would frequently have been better served starting.
What does the first year look like?
For a purchase, the first year is largely about retention and remediation. Patients and staff are deciding whether to stay, prescriber relationships are being re-established with a new face, and whatever diligence found is being corrected whilst the business trades. Revenue is present from day one and so is the work, and an owner who planned only for the trading is generally surprised by the remainder.
For a start-up, the first year is about proving demand. Revenue arrives slowly, the governance work happens before it produces anything, and the temptation to accelerate through advertising arrives precisely when the operation is least ready to absorb volume, which is the failure pattern the playbook describes.
Both share one characteristic worth planning for. The first year is when the habits are set, and a business which establishes proper records, review cycles and measurement in year one carries that advantage permanently, whilst one which defers them acquires a correction project which becomes harder each year it is deferred.
Key takeaways
- Buying acquires an NHS contract, a patient base, trading history and an operating business, and the last of these is where purchases go wrong when compliance is weak.
- Starting acquires nothing except the ability to build properly, which matters given that governance dominates inspection failures, at the cost of revenue, history and inherited demand.
- New NHS contracts are difficult to obtain through the pharmaceutical needs assessment framework, which is why new entry concentrates in distance-selling and private models.
- Valuation is a judgement about durability rather than a formula, and the factor most underpriced is dependence upon an owner-operator whose departure removes the pharmacist and the relationships.
- Regulatory diligence is financial diligence, since unresolved findings, weak records and undocumented arrangements are remediation costs with deadlines attached.
- Share and asset purchases carry different liability, tax and continuity consequences, and the regulatory position must be addressed properly in either case.
- Buying suits owners who improve things and need income immediately, starting suits owners with a specific model who can fund the wait, and buying in order to convert suits almost nobody.
FAQs
Year one sets the habits.
Whichever route an owner takes, the first year sets the habits, and records are the habit that compounds. Dataforge PMR gives a new business the audit trail a buyer would have paid a premium for, and gives a purchaser somewhere to rebuild one when diligence found it missing.
See Dataforge PMR